Enliven Therapeutics (ELVN) stock, explained like you're 5

Is Enliven Therapeutics a small, medium or large cap company?

No. Enliven Therapeutics is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 3 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Enliven Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves ELVN stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• Enliven Therapeutics, Inc. (ELVN) Stock Price, News, Quote & History (Yahoo! Finance Canada)
• A 23,394 option grant to director Ball at Enliven Therapeutics (ELVN) carries a $39.28 exercise price. (Stock Titan)
• Enliven Therapeutics, Inc. (ELVN) Adds Kristine Ball to Board (TradingView)
• Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
• Guggenheim reiterates Enliven Therapeutics stock rating on FDA alignment (Investing.com)

Key terms to know before you follow ELVN

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility